Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.

Abstract: The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The conjugates exhibit an excellent macrophage stimulant action and do not require addition solutizing. They can be used in a wide range of applications, in particular for stimulating macrophages, for stimulating antibody synthesis, for combating infection, as an immunostimulant, in particular in relation to tumors, for preventing and treating septicaemic shock, for would healing and as an adjuvant for vaccines.

Abstract: The invention relates to a method for marker-free DNA expression cassette exchange in the genome of cells or parts of cells by using the FLP recombinase mediated cassette exchange. A first DNA expression cassette carrying a positive-negative selection marker flanked by two FLP recombinase recognition target (FRT) sites is integrated into a chromosomal locus of the genome. Following selection of cell clones surviving the conditions for positive selection, the first DNA cassette is exchanged by an incoming second DNA expression cassette located on a circular vector and carrying a transgene flanked by the same FRT sites as the first DNA cassette by using FLP-recombinase. The cell clones surviving the conditions for negative selection contain specifically inserted the gene of the incoming DNA cassette without inserted unwanted vector sequences or positive selectable markers.

Abstract: The present invention relates to epothilon derivatives and to their use.

Abstract: The present invention relates to epothilon derivatives and to their use.

Abstract: The present invention relates to epothilon derivatives and to their use.

Abstract: Multicistronic expression units allow the equimolar expression of the genes located in the corresponding cistrons. These expression units are particularly suitable for the recombinant production of proteins composed of two or more polypeptide subunits.

Abstract: A single, unitary, solid phase support apparatus having a planar surface divided into a plurality of separate zone functions to detect antibodies. Each zone has bonded to it, a different peptide through its C-terminal end. The zones are incubated with the analyte sample and observed for reaction, indicating the virus-specific or bacteria specific presence or absence.

Abstract: The invention relates to a process for the production of a primer for consecutive DNA sequencing, in which at least two shortmers are hybridised adjacent to one another using a template and are then ligated with one another to form the primer, the process being characterised in that(a) a template in the form of a single strand of nucleotides is used in which the number of nucleotides is at least 6 and is not greater than approximately twice the total number of nucleotides of all the shortmers used, and(b) the primer formed is then separated from the template and from unreacted shortmers and recovered. The invention relates also to banks (libraries) of templates for the mentioned process.

Abstract: The invention relates to compounds which can be reacted with a carboxyl function with formation of an ester bond, whereby a protective group and, in particular, an anchor group for the carboxyl function is provided. The invention further relates to esters of acids which are obtainable by esterification with a compound according to the invention, and to the use of the compounds according to the invention in peptide synthesis.

Abstract: The invention relates to a hybrid transposon having a PT operon, to plasmids and to bacterial strains (hosts) therefor.

Abstract: The recombinant production of PDGF-AB in mammalian cells is disclosed by means of a bicistronic vector system in which an IRES sequence is located between the first and second cistrons and in which the B chain coding gene is located in the first cistron. The disclosed expression unit allows the equimolor expression of the A and B polypeptide chains.

Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Abstract: A water-soluble protein conjugate modified by saccharides is covalently bound to a carbohydrate backbone via a saccharide group. Such protein conjugates modified by saccharides can be produced in a simple way by polymerizing a vinylsaccharide and conjugating in a known way the poly(vinylsaccharide) obtained in this way with the protein, which is preferably an enzyme. The protein conjugates according to the present invention are stable over long time periods at a high enzymatic activity and also in aqueous solution and are thus particularly suitable for use in test kits.

Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: pPTH, bPTH or hPTH is modified by deletions from the natural C- and/or N-terminus. The modified compounds are useful active ingredients in therapeutic compositions. The therapeutic compositions do not stimulate renal adenylate cyclase but, rather, effect chondrocyte proliferation, that is to say, they exhibit a mitogenic and bone-specific effect.

Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.

Abstract: The invention relates to a method of preparing N.sup.6 -substituted NAD, NADP or FAD by Dimroth rearrangement, wherein the rearrangement is carried out without preceding reduction and subsequent reoxidation.